Experienced in Angiosarcoma of the Scalp

Dr. Ryan Ramaekers

Hematology Oncology | Hematology | Oncology
Oncology Hematology West, PC
7500 Mercy Rd, 
Omaha, NE 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Experienced in Angiosarcoma of the Scalp
Oncology Hematology West, PC
7500 Mercy Rd, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ryan Ramaekers is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Ramaekers is rated as an Experienced provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Mantle Cell Lymphoma (MCL), Familial Colorectal Cancer, Breast Cancer, and Lung Cancer.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IA
Hospital Affiliations
Henderson Community Hospital
Chi Health St. Francis
Brodstone Healthcare
Mary Lanning Healthcare
Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

ONCOLOGY HEMATOLOGY WEST, PC
7500 Mercy Rd, Omaha, NE 68124

Additional Areas of Focus

Dr. Ramaekers has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Cancer Moonshot Biobank Research Protocol
Cancer Moonshot Biobank Research Protocol
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Other
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Enrollment Status: Recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: KIN-2787
Study Phase: Phase 1
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Enrollment Status: Unknown
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

18 Total Publications

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152).
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152).
Journal: Cancer
Published: June 18, 2021
Similar Doctors
Advanced in Angiosarcoma of the Scalp
Dr. Kirsten Leu
Hematology Oncology | Oncology | Hematology
Advanced in Angiosarcoma of the Scalp
Dr. Kirsten Leu
Hematology Oncology | Oncology | Hematology

Oncology Hematology West, PC

17201 Wright St, Suite 200, 
Omaha, NE 
 (7.9 miles away)
402-334-4773
Languages Spoken:
English
See accepted insurances

Kirsten Leu is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Leu is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. Her top areas of expertise are Angiosarcoma, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, and Epithelioid Sarcoma.

Experienced in Angiosarcoma of the Scalp
Dr. Nagendra Natarajan
Hematology Oncology | Pediatrics | Hematology
Experienced in Angiosarcoma of the Scalp
Dr. Nagendra Natarajan
Hematology Oncology | Pediatrics | Hematology

Oncology Hematology West, PC

7500 Mercy Rd, Suite 1300, 
Omaha, NE 
 (0.1 miles away)
402-393-3110
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nagendra Natarajan is a Hematologist Oncology specialist and a Pediatrics provider in Omaha, Nebraska. Dr. Natarajan is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Thrombocytopenia. Dr. Natarajan is currently accepting new patients.

Experienced in Angiosarcoma of the Scalp
Dr. Robert M. Langdon
Hematology Oncology | Oncology | Hematology
Experienced in Angiosarcoma of the Scalp
Dr. Robert M. Langdon
Hematology Oncology | Oncology | Hematology

Oncology Hematology West, PC

7500 Mercy Rd, Suite 1300, 
Omaha, NE 
 (0.1 miles away)
402-393-3110
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Langdon is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Langdon is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Langdon is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ramaekers's expertise for a condition
ConditionClose
    View All 39 Distinguished Conditions
    View All 83 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile